DGIdb - ABCB1 Gene Record

ABCB1 5243 Druggable GenomeDrug Resistance

Alternate Names:

5243
ATP BINDING CASSETTE SUBFAMILY B MEMBER 1
ABCB1
ABC20
CD243
CLCS
GP170
MDR1
P-GP
PGY1
171050
40
ENSG00000085563
OTTHUMG00000023393
P08183
MDR1_HUMAN
4244
PA267
MULTIDRUG RESISTANCE PROTEIN 1 (P-GLYCOPROTEIN 1) (CD243 ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P08183]
CD_antigen=CD243
P-glycoprotein 1
ATP-binding cassette sub-family B member 1
Multidrug resistance protein 1
T25258
p-170

Gene Info:

Transmembrane Helix Count	12
Target Subclass	ABCB
Target Subclass	Active_transporters
Target Main Class	Transporters
Target Class	Transporters
Target Subclass	TC:3.A.1.201.1
Human Readable Name	DRUGGABLE GENOME
Uniprot Status	Swiss-Prot
Interpro Acc	IPR001140
Interpro Short Name	ABC_transptr_TM_dom
Interpro Type	Domain
Uniprot Evidence	1: Evidence at protein level
Interpro Name	ABC transporter, transmembrane domain
Human Readable Name	ABC TRANSPORTER
Gene Biotype	PROTEIN_CODING

(12 More Sources)

Gene Categories: Category Details

TRANSPORTER
CELL SURFACE
DRUG RESISTANCE
ABC TRANSPORTER
DRUGGABLE GENOME
ENZYME

Publications:

Baietto L et al., 2015, Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients., J Antimicrob Chemother
Gréen et al., 2006, mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy., Clin. Cancer Res.
Spletstoser JT et al., 2006, Single-site chemical modification at C10 of the baccatin III core of paclitaxel and Taxol C reduces P-glycoprotein interactions in bovine brain microvessel endothelial cells., Bioorg Med Chem Lett
Nanovskaya et al., 2005, Role of P-glycoprotein in transplacental transfer of methadone., Biochem. Pharmacol.
Uhr et al., 2004, P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6., J. Psychopharmacol. (Oxford)
Nievergelt A et al., 2010, Identification of serotonin 5-HT1A receptor partial agonists in ginger., Bioorg Med Chem
Marks KM et al., 2011, The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes., J Nat Prod
Juvale K et al., 2012, Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein., Bioorg Med Chem
Ehmann F et al., 2014, European Medicines Agency initiatives and perspectives on pharmacogenomics., Br J Clin Pharmacol
Ghanem et al., 2006, Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin., J. Pharmacol. Exp. Ther.
Brandes et al., 2000, N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs., Cancer Chemother. Pharmacol.
Vincent, 2006, Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump., Med. Hypotheses
D'Emanuele et al., 2004, The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability., J Control Release
Cunningham CW et al., 2008, Opioids and efflux transporters. Part 2: P-glycoprotein substrate activity of 3- and 6-substituted morphine analogs., J Med Chem
Saiz-Rodríguez M et al., 2018, Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants., Basic Clin Pharmacol Toxicol
Wang R et al., 2018, ABCB1 1199G > A Polymorphism Impacts Transport Ability of P-gp-Mediated Antipsychotics., DNA Cell Biol
Vandenberghe F et al., 2015, Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort., Clin Pharmacokinet
Suzuki Y et al., 2014, Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia., Pharmacogenomics J
Choong E et al., 2013, Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects., J Clin Psychopharmacol
Correia CT et al., 2010, Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions., Pharmacogenomics J
Ogino J et al., 1996, Dendroamides, new cyclic hexapeptides from a blue-green alga. Multidrug-resistance reversing activity of dendroamide A., J Nat Prod
Kang et al., 2007, The effect of MDR1 G2677T/A polymorphism on pharmacokinetics of gabapentin in healthy Korean subjects., Arch. Pharm. Res.
Zhang Y et al., 2017, Correlation of MDR1 gene polymorphism with propofol combined with remifentanil anesthesia in pediatric tonsillectomy., Oncotarget
Roberts RL et al., 2002, A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression., Pharmacogenomics J
Colabufo NA et al., 2008, Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents., J Med Chem
Asano T et al., 2003, ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation., Pharmacogenetics
Yokoi M et al., 2018, Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy., Support Care Cancer
Tsuji D et al., 2017, Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study., Pharmacogenomics J
Weiss J et al., 2009, CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole., J Clin Pharmacol
Tong L et al., 2007, Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro., Antimicrob Agents Chemother
Liu X et al., 2017, Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus., Pharmacotherapy
Tsai MS et al., 2017, Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study., J Microbiol Immunol Infect
Bonora S et al., 2015, Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)., J Antimicrob Chemother
Avihingsanon A et al., 2015, Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia., J Acquir Immune Defic Syndr
Nishijima T et al., 2014, Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study., J Antimicrob Chemother
D'Avolio A et al., 2014, Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms., J Antimicrob Chemother
Coelho AV et al., 2013, ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients., J Clin Pharmacol
Lubomirov R et al., 2011, Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study., J Infect Dis
Park WB et al., 2010, Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency., Clin Infect Dis
Ma Q et al., 2007, Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV., Pharmacogenomics
Rodríguez-Nóvoa S et al., 2007, Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia., AIDS
Hogg M et al., 1991, Chloride influx in human leucocytes: a triple-isotope technique for the assessment of chloride transporters., Clin Sci (Lond)
Rodríguez Nóvoa et al., 2006, Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1., Clin. Infect. Dis.
Haas DW et al., 2003, MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study., J Acquir Immune Defic Syndr
Gregers J et al., 2015, Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia., Pharmacogenomics J
Castañeda-Gómez J et al., 2013, Purgin II, a resin glycoside ester-type dimer and inhibitor of multidrug efflux pumps from Ipomoea purga., J Nat Prod
Figueroa-González G et al., 2012, Reversal of multidrug resistance by morning glory resin glycosides in human breast cancer cells., J Nat Prod
Aubrun F et al., 2018, Opioid-related genetic polymorphisms do not influence postoperative opioid requirement: A prospective observational study., Eur J Anaesthesiol
Sadhasivam S et al., 2015, Opioid-induced respiratory depression: ABCB1 transporter pharmacogenetics., Pharmacogenomics J
Venkatasubramanian R et al., 2014, ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children., Pharmacogenomics
Bastami S et al., 2014, Influence of UGT2B7, OPRM1 and ABCB1 gene polymorphisms on postoperative morphine consumption., Basic Clin Pharmacol Toxicol
Lötsch J et al., 2009, Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers., Pharmacogenet Genomics
Campa D et al., 2008, Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief., Clin Pharmacol Ther
Coulbault L et al., 2006, Environmental and genetic factors associated with morphine response in the postoperative period., Clin Pharmacol Ther
Zembruski NC et al., 2011, Interaction potential of etravirine with drug transporters assessed in vitro., Antimicrob Agents Chemother
Naito T et al., 2011, CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone., J Clin Pharmacol
Sakaeda et al., 2005, Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs., J. Pharm. Pharmacol.
Bercovich D et al., 2006, The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia., Atherosclerosis
Kim et al., 1999, Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein., Pharm. Res.
Jordheim LP et al., 2015, Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma., Haematologica
Moresco M et al., 2016, Pharmacogenetics and Treatment Response in Narcolepsy Type 1: Relevance of the Polymorphisms of the Drug Transporter Gene ABCB1., Clin Neuropharmacol
Han et al., 2006, Effects of capsaicin on P-gp function and expression in Caco-2 cells., Biochem. Pharmacol.
He H et al., 2014, Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting., Clin Ther
Choi EM et al., 2010, Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting., Anaesthesia
Zheng H et al., 2002, The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients., Hum Immunol
Ghetie et al., Rituximab but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P-glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts., J. Immunother.
He H et al., 2015, Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia., Eur J Clin Pharmacol
Megías-Vericat JE et al., 2015, Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies., Pharmacogenomics J
Gréen H et al., 2012, Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype., Pharmacogenomics J
Kim DH et al., 2006, Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia., Int J Cancer
Chen et al., 2005, Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1., Drug Metab. Dispos.
Mega JL et al., 2009, Identification of genetic variants associated with response to statin therapy., Arterioscler Thromb Vasc Biol
Lou K et al., 2014, Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies., J Med Chem
Silva GL et al., 2001, Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei., J Nat Prod
Liu XL et al., 2008, Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein., Bioorg Med Chem
Juvale K et al., 2012, 4-Substituted-2-phenylquinazolines as inhibitors of BCRP., Bioorg Med Chem Lett
Condello M et al., 2014, Voacamine modulates the sensitivity to doxorubicin of resistant osteosarcoma and melanoma cells and does not induce toxicity in normal fibroblasts., J Nat Prod
Sánchez-Lázaro I et al., 2015, Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation., Pharmacogenomics
Lee J et al., 2015, The Effect of ABCB1 C3435T Polymorphism on Cyclosporine Dose Requirements in Kidney Transplant Recipients: A Meta-Analysis., Basic Clin Pharmacol Toxicol
Sharaki O et al., 2015, Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients., Mol Biol Rep
Ferraresso M et al., 2013, Long-term effects of ABCB1 and SXR SNPs on the systemic exposure to cyclosporine in pediatric kidney transplant patients., Pharmacogenomics
Barbarino JM et al., 2013, PharmGKB summary: cyclosporine and tacrolimus pathways., Pharmacogenet Genomics
García M et al., 2013, ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients., Eur J Clin Pharmacol
Santoro A et al., 2011, Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients., Pharmacogenomics
Yanagimachi M et al., 2010, Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation., Clin Transplant
Zhang YT et al., 2008, ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients., Br J Clin Pharmacol
Beringer PM et al., 2008, Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis., Pharmacotherapy
Grinyó J et al., 2008, Association of four DNA polymorphisms with acute rejection after kidney transplantation., Transpl Int
Crettol S et al., 2008, Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients., Pharmacogenet Genomics
Daniel F et al., 2007, Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis., Inflamm Bowel Dis
Hesselink DA et al., 2003, Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus., Clin Pharmacol Ther
Herweijer et al., 1990, Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine., J. Natl. Cancer Inst.
Perroud N et al., 2011, Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample., Pharmacogenomics
Mukonzo JK et al., 2013, Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study., BMC Infect Dis
Elens L et al., 2010, Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients., Pharmacogenomics
Ribaudo HJ et al., 2010, Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study., J Infect Dis
Ritchie MD et al., 2006, Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity., Clin Infect Dis
Haas DW et al., 2005, Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study., J Infect Dis
Fellay J et al., 2002, Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study., Lancet
Goldsborough AS et al., 2011, Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin., J Med Chem
Roberts RL et al., 2015, Pharmacogenetic considerations in the treatment of gout., Pharmacogenomics
Brandt et al., 2006, The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy., Neurobiol. Dis.
Keangpraphun T et al., 2015, Association of ABCB1 C3435T polymorphism with phenobarbital resistance in Thai patients with epilepsy., J Clin Pharm Ther
Li M et al., 2018, ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia., Pharmacogenomics J
Kim SW et al., 2013, ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD., J Clin Psychopharmacol
Banerjee et al., 1992, Down-regulation of ras and myc expression associated with mdr-1 overexpression in adriamycin-resistant tumor cells., Cell. Mol. Biol.
Ando et al., 2000, Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells., Leukemia
Mealey et al., 2002, Doxycycline induces expression of P glycoprotein in MCF-7 breast carcinoma cells., Antimicrob. Agents Chemother.
Pertusini et al., 2001, Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy., Blood
Molnar et al., New silicon compounds as resistance modifiers against multidrug-resistant cancer cells., Anticancer Res.
Limtrakul et al., 2004, Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids., BMC Cancer
Kim RB et al., 2001, Identification of functionally variant MDR1 alleles among European Americans and African Americans., Clin Pharmacol Ther
Wartenberg et al., 2003, Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species., FASEB J.
Breitenstein B et al., 2016, Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study., J Psychiatr Res
Huang X et al., 2013, ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients., Pharmacogenomics
de Klerk OL et al., 2013, ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder., Pharmacogenomics J
Uhr M et al., 2008, Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression., Neuron
Aksentijevich et al., 1996, Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity., Clin. Cancer Res.
Billat PA et al., 2016, Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients., Pharmacol Res
Miura M et al., 2006, Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus., Int J Clin Pharmacol Ther
Gervasini et al., 2006, The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study., Br J Clin Pharmacol
Wang et al., 2001, Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein., Drug Metab. Dispos.
Langer et al., 2004, [Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis]., Verh Dtsch Ges Pathol
Hou X et al., 2018, CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment., J Clin Lab Anal
Danielak D et al., 2017, Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite., Eur J Clin Pharmacol
Olędzki S et al., 2017, Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention., Eur J Clin Pharmacol
Zhai Y et al., 2017, Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease., Eur J Clin Pharmacol
Su J et al., 2017, The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population., PLoS One
Saydam F et al., 2017, The CYP2C192 and CYP2C1917 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study., Basic Clin Pharmacol Toxicol
Zhang HZ et al., 2017, CYP2C19 but not CYP2B6, CYP3A4, CYP3A5, ABCB1, PON1 or P2Y12 genetic polymorphism impacts antiplatelet response after clopidogrel in Koreans., Blood Coagul Fibrinolysis
Calderón-Cruz B et al., 2015, C3435T polymorphism of the ABCB1 gene is associated with poor clopidogrel responsiveness in a Mexican population undergoing percutaneous coronary intervention., Thromb Res
So DY et al., 2016, A prospective randomized evaluation of a pharmacogenomic approach to antiplatelet therapy among patients with ST-elevation myocardial infarction: the RAPID STEMI study., Pharmacogenomics J
Wang XQ et al., 2015, Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome., Gene
Karaźniewicz-Łada M et al., 2015, Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites., J Clin Pharm Ther
Latkovskis G et al., 2014, Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness., Medicina (Kaunas)
Cresci S et al., 2014, Cytochrome p450 gene variants, race, and mortality among clopidogrel-treated patients after acute myocardial infarction., Circ Cardiovasc Genet
Xie C et al., 2014, The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease., Pharmacogenet Genomics
Viviani Anselmi C et al., 2013, Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease., JACC Cardiovasc Interv
Zhang L et al., 2013, Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients., Thromb Res
Carlquist JF et al., 2013, Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes., Thromb Haemost
Tang XF et al., 2013, Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention., Eur J Clin Pharmacol
Su J et al., 2012, ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis., PLoS One
Wu H et al., 2012, Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China., Pharmacogenet Genomics
Verschuren JJ et al., 2013, Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction., Int J Cardiol
Chen DY et al., 2012, Paraoxonase-1 is not a major determinant of stent thrombosis in a Taiwanese population., PLoS One
Price MJ et al., 2012, Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study., J Am Coll Cardiol
Bonello L et al., 2012, Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade., Thromb Res
Delaney JT et al., 2012, Predicting clopidogrel response using DNA samples linked to an electronic health record., Clin Pharmacol Ther
Jeong YH et al., 2011, Effect of CYP2C192 and 3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin., Circ Cardiovasc Interv
Cayla G et al., 2011, Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis., JAMA
Simon T et al., 2011, Effect of paraoxonase-1 polymorphism on clinical outcomes in patients treated with clopidogrel after an acute myocardial infarction., Clin Pharmacol Ther
Kassimis G et al., 2012, CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary intervention., Thromb Res
Rideg O et al., 2011, Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention., Pharmacogenomics
Wallentin L et al., 2010, Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial., Lancet
Mega JL et al., 2010, Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis., Lancet
Jeong YH et al., 2010, Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study., JACC Cardiovasc Interv
Simon T et al., 2009, Genetic determinants of response to clopidogrel and cardiovascular events., N Engl J Med
Taubert D et al., 2006, Impact of P-glycoprotein on clopidogrel absorption., Clin Pharmacol Ther
Chu et al., 1999, Active efflux of CPT-11 and its metabolites in human KB-derived cell lines., J. Pharmacol. Exp. Ther.
Yamazaki et al., 2005, Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport., Xenobiotica
Kishi S et al., 2004, Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia., Blood
Collett et al., 1999, Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2., J. Pharmacol. Exp. Ther.
Mickisch et al., 1991, Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance., Proc. Natl. Acad. Sci. U.S.A.
Meschini et al., 2005, Voacamine, an alkaloid extracted from Peschiera fuchsiaefolia, inhibits P-glycoprotein action in multidrug-resistant tumor cells., Int. J. Oncol.
Meschini et al., 2003, Voacamine, a bisindolic alkaloid from Peschiera fuchsiaefolia, enhances the cytotoxic effect of doxorubicin on multidrug-resistant tumor cells., Int. J. Oncol.
Ciccacci C et al., 2010, Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique., Pharmacogenomics
Haas DW et al., 2006, Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration., Clin Infect Dis
Orlowski et al., 1998, Bromocriptine modulates P-glycoprotein function., Biochem. Biophys. Res. Commun.
Shiraki et al., 2002, Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells., Jpn. J. Cancer Res.
Leggas et al., 2006, Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo., Cancer Res.
Ma Y et al., 2017, Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters., Pharmacogenomics J
Kobayashi H et al., 2015, Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer., Clin Lung Cancer
Ozvegy-Laczka et al., 2004, High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter., Mol. Pharmacol.
Oshiro C et al., 2009, Taxane pathway., Pharmacogenet Genomics
Cummins et al., 2004, CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam., J. Pharmacol. Exp. Ther.
Mbatchi LC et al., 2017, Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer., Cancer Chemother Pharmacol
Sam WJ et al., 2012, Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients., Transplantation
Hubensack et al., 2008, Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice., J. Cancer Res. Clin. Oncol.
Gurley et al., 2006, Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans., Drug Metab. Dispos.
Ghodke Y et al., 2012, PharmGKB summary: zidovudine pathway., Pharmacogenet Genomics
Jorajuria et al., 2004, ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages., Antivir. Ther. (Lond.)
El Ela et al., 2004, Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates., J. Pharm. Pharmacol.
Mark et al., 2006, P-glycoprotein restricts access of cortisol and dexamethasone to the glucocorticoid receptor in placental BeWo cells., Endocrinology
Breedveld et al., 2005, The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients., Cancer Res.
Malmström A et al., 2020, ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide., Pharmacogenomics J
Peck et al., 2001, Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin., J. Clin. Oncol.
Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
Caronia D et al., 2011, Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study., PLoS One
Lal S et al., 2008, Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients., Cancer Sci
Maggini V et al., 2008, MDR1 diplotypes as prognostic markers in multiple myeloma., Pharmacogenet Genomics
Miyachi et al., 1999, Microsatellite instability and clonal heterogeneity of MDR1 messenger RNA expression in trimetrexate-resistant human leukemia MOLT-3 cells developed in thymidine., Int. J. Cancer
Jakubíková et al., 2001, Non-steroidal anti-inflammatory agent ibuprofen-induced apoptosis, cell necrosis and cell cycle alterations in human leukemic cells in vitro., Neoplasma
Cusato J et al., 2015, Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics., Int J Antimicrob Agents
Tan ZR et al., 2015, The influence of ABCB1 polymorphism C3435T on the pharmacokinetics of silibinin., J Clin Pharm Ther
Li XQ et al., 2015, Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives., Eur J Med Chem
Gawrońska-Szklarz B et al., 2005, Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection., Eur J Clin Pharmacol
Sparreboom A et al., 2004, Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients., Invest New Drugs
Nies AT et al., 2008, Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1)., Naunyn Schmiedebergs Arch Pharmacol
Nesi G et al., 2014, SAR study on arylmethyloxyphenyl scaffold: looking for a P-gp nanomolar affinity., Eur J Med Chem
Perestelo NR et al., 2011, Overcoming human P-glycoprotein-dependent multidrug resistance with novel dihydro-β-agarofuran sesquiterpenes., Eur J Med Chem
Chae SW et al., 2015, Xanthone analogues as potent modulators of intestinal P-glycoprotein., Eur J Med Chem
Tang X et al., 2012, Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells., Bioorg Med Chem Lett
Gu X et al., 2012, Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors., Eur J Med Chem
Gu X et al., 2012, Synthesis and biological evaluation of bifendate-chalcone hybrids as a new class of potential P-glycoprotein inhibitors., Bioorg Med Chem
Liu J et al., 2013, 20(S)-Protopanaxadiol (PPD) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs., Bioorg Med Chem
Kónya et al., 2006, Inhibition of the MDR1 transporter by new phenothiazine derivatives., Biochem. Biophys. Res. Commun.
Zhang J et al., 2018, Association between MDR<sub>1</sub>/CYP3A4/OPRM<sub>1</sub> gene polymorphisms and the post-caesarean fentanyl analgesic effect on Chinese women., Gene
Dzambazovska-Trajkovska V et al., 2016, Association of Single-Nucleotide Polymorhism C3435T in the ABCB1 Gene with Opioid Sensitivity in Treatment of Postoperative Pain., Pril (Makedon Akad Nauk Umet Odd Med Nauki)
Kim KM et al., 2013, Effects of genetic polymorphisms of OPRM1, ABCB1, CYP3A4/5 on postoperative fentanyl consumption in Korean gynecologic patients., Int J Clin Pharmacol Ther
Takashina Y et al., 2012, Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system., Drug Metab Pharmacokinet
Park HJ et al., 2007, Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans., Clin Pharmacol Ther
Wandel C et al., 2002, Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein., Anesthesiology
Sangkuhl K et al., 2011, PharmGKB summary: citalopram pharmacokinetics pathway., Pharmacogenet Genomics
Gouin-Thibault I et al., 2017, Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin., J Thromb Haemost
Wang et al., 2005, P-glycoprotein does not actively transport nicotine and cotinine., Addict Biol
Dimatteo C et al., 2016, Pharmacogenetics of dabigatran etexilate interindividual variability., Thromb Res
Rybczynska et al., 2001, MDR1 causes resistance to the antitumour drug miltefosine., Br. J. Cancer
Bailly et al., 1995, Effect of 5637-conditioned medium and recombinant cytokines on P-glycoprotein expression in a human GM-CSF-dependent leukemic myeloid cell line., Leukemia
Ge H et al., 2006, Synthesis and interactions of 7-deoxy-, 10-deacetoxy, and 10-deacetoxy-7-deoxypaclitaxel with NCI/ADR-RES cancer cells and bovine brain microvessel endothelial cells., Bioorg Med Chem Lett
Zubiaur P et al., 2020, Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers., Pharmacogenomics J
Mukonzo JK et al., 2016, CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population., Pharmacogenomics
Cusato J et al., 2016, Efavirenz pharmacogenetics in a cohort of Italian patients., Int J Antimicrob Agents
Mukonzo JK et al., 2014, CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure., Pharmacogenomics
Mukonzo JK et al., 2014, Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes., PLoS One
Cabrera Figueroa S et al., 2010, The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy., Ther Drug Monit
Chen J et al., 2010, CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients., Ther Drug Monit
Csajka C et al., 2003, Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection., Clin Pharmacol Ther
Tavares LC et al., 2018, Association Between <i>ABCB1</i> Polymorphism and Stable Warfarin Dose Requirements in Brazilian Patients., Front Pharmacol
Bryk AH et al., 2018, Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms., Vascul Pharmacol
de Oliveira Almeida VC et al., 2014, Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study., Mol Diagn Ther
Zhang W et al., 2012, Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism., Pharmacogenomics
Elgie et al., 1999, Comparison of P-glycoprotein expression and function with in vitro sensitivity to anthracyclines in AML., Adv. Exp. Med. Biol.
Jakobsen Falk I et al., 2018, Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial., Cancer Chemother Pharmacol
Sistonen J et al., 2012, Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers., Clin Pharmacol Ther
Becker ML et al., 2009, Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males., Pharmacogenomics
Becker ML et al., 2010, Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy., Pharmacoepidemiol Drug Saf
Fiegenbaum et al., 2005, The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment., Clin. Pharmacol. Ther.
Zhao W et al., 2018, Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug., Br J Clin Pharmacol
Zhou X et al., 2015, Miltirone Is a Dual Inhibitor of P-Glycoprotein and Cell Growth in Doxorubicin-Resistant HepG2 Cells., J Nat Prod
Zhu et al., 2006, Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana., J. Pharmacol. Exp. Ther.
Gao C et al., 2012, Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics., Drug Metab Dispos
Kadam P et al., 2016, Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population., J Clin Pharm Ther
Hoenig MR et al., 2011, The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort., J Clin Lipidol
Keskitalo JE et al., 2008, ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin., Clin Pharmacol Ther
Rebecchi IM et al., 2009, ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment., Biochem Pharmacol
Thompson JF et al., 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response., Pharmacogenomics J
Jeleń AM et al., 2015, The Influence of C3435T Polymorphism of the ABCB1 Gene on Genetic Susceptibility to Depression and Treatment Response in Polish Population - Preliminary Report., Int J Med Sci
Jiménez-Varo E et al., 2014, Pharmacogenetics role in the safety of acenocoumarol therapy., Thromb Haemost
He X et al., 2012, Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism., Xenobiotica
Giovannetti E et al., 2011, Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy., Pharmacogenomics
Gonzalez-Haba E et al., 2010, ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients., Pharmacogenomics
Wang et al., 2003, The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2., Chemotherapy
Chan SL et al., 2017, Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients., PLoS One
Yimer G et al., 2011, Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients., PLoS One
Cramer JP et al., 2010, Low N-acetyltransferase 2 activity in isoniazid-associated acute hepatitis requiring liver transplantation., Transpl Int
Shen C et al., 2017, Effects of ABCB1, ABCC2, UGT2B7 and HNF4α genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy., Seizure
Matsui et al., 2002, Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers., Leukemia
Wang et al., 2006, Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein., Psychopharmacology (Berl.)
Sharma A et al., 2012, Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies., Drugs
Liu et al., Effect of P-glycoprotein inhibitors erythromycin and cyclosporin A on brain pharmacokinetics of nimodipine in rats., Eur J Drug Metab Pharmacokinet
Numakura K et al., 2017, Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib., Anticancer Drugs
Chu YH et al., 2015, Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma., PLoS One
Teo YL et al., 2016, Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients., Pharmacogenomics J
Beuselinck B et al., 2014, Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib., Acta Oncol
Kim HR et al., 2013, Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients., Cancer Chemother Pharmacol
Gassó P et al., 2014, Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients., Pharmacogenomics J
Laurenty AP et al., 2013, Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report., Pharmacogenomics
Gollapudi et al., 1997, Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells., Cancer Chemother. Pharmacol.
van der Weide K et al., 2017, Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population., Pharmacogenomics J
Lee ST et al., 2012, Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response., J Clin Psychopharmacol
Jaquenoud Sirot E et al., 2009, ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine., J Clin Psychopharmacol
Mei Y et al., 2015, Role of SLCO1B1, ABCB1, and CHRNA1 gene polymorphisms on the efficacy of rocuronium in Chinese patients., J Clin Pharmacol
Göktaş MT et al., 2016, Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients., Eur Rev Med Pharmacol Sci
Alenius M et al., 2008, Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting., J Psychiatr Res
Lin YC et al., 2006, The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia., Ther Drug Monit
Foster et al., An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic., J Pharm Pharm Sci
Wu H et al., 2013, Association of ABCB1 genetic polymorphisms with susceptibility to colorectal cancer and therapeutic prognosis., Pharmacogenomics
Narumiya K et al., 2011, Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer., Pharmacogenomics
McLeod HL et al., 2010, Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741., J Clin Oncol
Putnam WS et al., 2005, Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics., J Clin Pharmacol
Deguchi Y et al., 2008, Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines., Leuk Res
Katayama R et al., 2015, P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer., EBioMedicine

VOACAMINE ABCB1

Interaction Score: 1.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
16273216 14612920 24720452

Sources:
DTC
ZOSUQUIDAR ABCB1

Interaction Score: 0.77

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name zosuquidar, LY335979

Novel drug target Novel Target

PMIDs:
18157518

Sources:
TdgClinicalTrial PharmGKB
TARIQUIDAR ABCB1

Interaction Score: 0.64

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction P-glycoprotein 1 inhibitor

Direct Interaction yes

Trial Name tariquidar

PMIDs:
21657271

Sources:
DTC TdgClinicalTrial ChemblInteractions PharmGKB
PERVILLEINE D ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11754602

Sources:
DTC
EPOTHILONE D ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24992153

Sources:
DTC
BRECANAVIR ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17664327

Sources:
DTC
CHEMBL306786 ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16271474

Sources:
DTC
CHEMBL203365 ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16271474

Sources:
DTC
PERVILLEINE F ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11754602

Sources:
DTC
CHEMBL408422 ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18311899

Sources:
DTC
PERVILLEINE C ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11754602

Sources:
DTC
AUSTOCYSTIN D ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21348461

Sources:
DTC
CHEMBL410907 ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18311899

Sources:
DTC
PERVILLEINE B ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11754602

Sources:
DTC
TAXOL C ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16289636

Sources:
DTC
CHEMBL595816 ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22112540

Sources:
DTC
BISANTRENE ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9816258

Sources:
NCI
FLAVOKAWAIN A ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22112540

Sources:
DTC
CHEMBL217425 ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18257545

Sources:
DTC
PURGIN II ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23273047

Sources:
DTC
MURUCOIDIN V ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22148475

Sources:
DTC
CHEMBL270688 ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18257545

Sources:
DTC
BIRICODAR ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB TTD
DENDROAMIDE A ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8786364

Sources:
DTC
HETEROCODEINE ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18311899

Sources:
DTC
DAPTOMYCIN ABCB1

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25239468

Sources:
PharmGKB
CLOPIDOGREL ABCB1

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29397568 28914344 28589365 28378058 28358842 28135763 27380588 26362473 25850030 25542807 25430046 25060201 24762860 24535487 24262617 23726091 23364775 23150151 23056288 22990067 22940005 22723959 22624833 22285300 22190063 22045970 22028352 21918510 21831410 21806387 20801498 20801494 20650435 19106083 17112805

Sources:
PharmGKB
NELFINAVIR ABCB1

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17664327 23734829 20860463 20662624 16912956 16267764 11809184

Sources:
DTC PharmGKB
3,4-DIHYDROXYXANTHONE ABCB1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
METOCHALCONE ABCB1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22112540

Sources:
DTC
GEMTUZUMAB OZOGAMICIN ABCB1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11986941

Sources:
NCI
TALINOLOL ABCB1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22725663

Sources:
PharmGKB
VALSPODAR ABCB1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CHEMBL444075 ABCB1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26197160

Sources:
DTC
IVERMECTIN ABCB1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DIHYDRO-12-HYDROXY-2,2-DIMETHYL-2H,6H-PYRANO[3,2-B]XANTHEN-6-ONE ABCB1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
MEFLOQUINE ABCB1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ELACRIDAR ABCB1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17932689

Sources:
PharmGKB
VALGANCICLOVIR ABCB1

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27402191

Sources:
PharmGKB
RITONAVIR ABCB1

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17664327 28718515 26857335 26174719 25622064 25151207 24997317 23996099 21288825 20504240 17324111 17148966 1655344 16355344 14600574

Sources:
DTC PharmGKB
DEXRAZOXANE ABCB1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25567217 25558979 20938465 16331627

Sources:
PharmGKB
EFAVIRENZ ABCB1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31628422 27045425 26774523 25303294 24497997 23734829 20860463 20720517 20662624 20625352 16912956 16267764 12545140 11809184 21189339

Sources:
DTC PharmGKB
DICLOXACILLIN ABCB1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18576903 15778422

Sources:
PharmGKB
TRABECTEDIN ABCB1

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24024892

Sources:
PharmGKB
LONAFARNIB ABCB1

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14671431

Sources:
NCI
SCUTELLARIN ABCB1

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22822035

Sources:
DTC
RIVAROXABAN ABCB1

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27893182

Sources:
PharmGKB
FEXOFENADINE ABCB1

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11503014

Sources:
PharmGKB
DOMPERIDONE ABCB1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15285840

Sources:
NCI PharmGKB
VENLAFAXINE ABCB1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26757307 26704739 26664259 24192121 22641028 21449676 18215618

Sources:
PharmGKB
BAFETINIB ABCB1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18191450

Sources:
CIViC
HYDROXOCOBALAMIN ABCB1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VINDESINE ABCB1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25637052

Sources:
PharmGKB
2',4'-DIHYDROXYCHALCONE ABCB1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22112540

Sources:
DTC
ETRAVIRINE ABCB1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21189339

Sources:
DTC
CODEINE ABCB1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18311899 22398969

Sources:
DTC PharmGKB
VECURONIUM ABCB1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SPARFLOXACIN ABCB1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VERAPAMIL ABCB1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9862768 1671173 18257545 24607999 21856049 25686592 21348461 22209486 22405646 22429509 17964170 20363635 24992153 23683834 11754602

Sources:
DTC NCI
QUERCETIN-3'-O-PHOSPHATE ABCB1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name LIM-0705

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial
CELIPROLOL ABCB1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ALISKIREN ABCB1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VALINOMYCIN ABCB1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LOPINAVIR ABCB1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23996099 17664327

Sources:
DTC PharmGKB
TESMILIFENE ABCB1

Interaction Score: 0.11

Interaction Types & Directionality:

inducer (activating)

Interaction Info:

Trial Name tesmilifene

Novel drug target Novel Target

PMIDs:
10755318 16413681

Sources:
TdgClinicalTrial
MILTIRONE ABCB1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26339922

Sources:
DTC
MILTEFOSINE ABCB1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11355955

Sources:
NCI
TIPIFARNIB ABCB1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15122075

Sources:
PharmGKB
DELAVIRDINE ABCB1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21189339

Sources:
DTC
REMIFENTANIL ABCB1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29755652

Sources:
PharmGKB
CYCLOSPORINE ABCB1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24992153 11754602 17964170 23017888 24720452 21348461 26107754 25536375 25240575 24088131 23922006 22886152 21806386 20030680 18717915 18576903 18444945 18334915 17206635 12966368 1972761

Sources:
DTC NCI PharmGKB
AMITRIPTYLINE ABCB1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26704739 24192121 22641028 18215618

Sources:
PharmGKB
TERFENADINE ABCB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16842392 11454724 10213372

Sources:
NCI PharmGKB
ROCURONIUM ABCB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25279974

Sources:
PharmGKB
FLUVOXAMINE ABCB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26704739 22641028 18215618

Sources:
PharmGKB
ACENOCOUMAROL ABCB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24919870

Sources:
PharmGKB
CYANOCOBALAMIN ABCB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DABIGATRAN ABCB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27893182 27261537

Sources:
PharmGKB
TETRABENAZINE ABCB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ONDANSETRON ABCB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25012726 20707787

Sources:
PharmGKB
PENTAZOCINE ABCB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
OXYCODONE ABCB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21209234 19514130

Sources:
PharmGKB
VORICONAZOLE ABCB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19033450

Sources:
PharmGKB
2'-HYDROXYCHALCONE ABCB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22112540

Sources:
DTC
DEXTROMETHORPHAN ABCB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15582917

Sources:
NCI
MORPHINE ABCB1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29474345 25311385 25155932 24703092 19514130 17898703 16580900 18311899

Sources:
DTC PharmGKB
FENTANYL ABCB1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29601950 27883323 23557865 22277678 19514130 17192767 11964599

Sources:
PharmGKB
ISONIAZID ABCB1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29036176 22162992 19686464

Sources:
PharmGKB
QUINIDINE ABCB1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1671173

Sources:
NCI PharmGKB
ITRACONAZOLE ABCB1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15969931

Sources:
NCI PharmGKB
PROBENECID ABCB1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9182837

Sources:
NCI
PANTOPRAZOLE ABCB1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15976989

Sources:
PharmGKB
BOCEPREVIR ABCB1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25836019

Sources:
PharmGKB
RITUXIMAB ABCB1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16971809 25637052

Sources:
NCI PharmGKB
RANOLAZINE ABCB1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24433361

Sources:
PharmGKB
NEVIRAPINE ABCB1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20017669 16912957 16912956 21189339

Sources:
DTC PharmGKB
LEVOFLOXACIN ABCB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DRONABINOL ABCB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16439618

Sources:
NCI
AMPRENAVIR ABCB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
BROMPERIDOL ABCB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PAROXETINE ABCB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26704739 24192121 22641028 21449676 18215618

Sources:
PharmGKB
DOXYCYCLINE ABCB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11850258

Sources:
NCI PharmGKB
TANGERETIN ABCB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SERTRALINE ABCB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26704739 24192121 22641028 18215618

Sources:
PharmGKB
CLARITHROMYCIN ABCB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16221754

Sources:
NCI PharmGKB
GRANISETRON ABCB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29177570 27241063

Sources:
PharmGKB
LOSARTAN ABCB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27338075

Sources:
PharmGKB
TRIMETREXATE ABCB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10360822

Sources:
NCI
ATAZANAVIR ABCB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16355344

Sources:
NCI
AMISULPRIDE ABCB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29443543

Sources:
PharmGKB
RANITIDINE ABCB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9862768

Sources:
NCI PharmGKB
GARLIC ABCB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11466175

Sources:
NCI
FILGRASTIM ABCB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7564516

Sources:
NCI
NITRENDIPINE ABCB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ALDOSTERONE ABCB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
NEFAZODONE ABCB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21449676

Sources:
PharmGKB
MODAFINIL ABCB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26757307

Sources:
PharmGKB
AGOMELATINE ABCB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
BROMOCRIPTINE ABCB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9514944 11856485

Sources:
NCI
PROPRANOLOL ABCB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15023456

Sources:
NCI PharmGKB
CERITINIB ABCB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26870817

Sources:
CIViC
CITALOPRAM ABCB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26704739 24192121 22641028 21546862 18215618

Sources:
PharmGKB
NORTRIPTYLINE ABCB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12082591

Sources:
PharmGKB
MICONAZOLE ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15969931

Sources:
NCI
ARIPIPRAZOLE ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29443543

Sources:
PharmGKB
SILIBININ ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26595166

Sources:
PharmGKB
CLOMIPRAMINE ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21449676

Sources:
PharmGKB
RESERPINE ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23273047 22148475

Sources:
DTC PharmGKB
ZIDOVUDINE ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23996099 22960662 15456083

Sources:
NCI PharmGKB
ADRIAMYCIN ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1363885 11069027

Sources:
NCI
SPIRONOLACTONE ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16740618

Sources:
NCI PharmGKB
SUNITINIB ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27564227 26244574 25778465 24874929 24013576

Sources:
PharmGKB
ATORVASTATIN ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26932749 21392722 19802823 19238649 18851956 16103896 15616150

Sources:
NCI PharmGKB
FLUOXETINE ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24663076 24192121 18215618

Sources:
PharmGKB
CHLORPROMAZINE ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16810505

Sources:
NCI PharmGKB
LENALIDOMIDE ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29177954

Sources:
PharmGKB
SUFENTANIL ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LEVETIRACETAM ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DEFEROXAMINE ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12514119

Sources:
NCI
WARFARIN ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29875668 29432897 25312789 22248286

Sources:
PharmGKB
IDARUBICIN ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25567217 25558979 20938465 16331627

Sources:
PharmGKB
CAPSAICIN ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16674925

Sources:
NCI
NIMODIPINE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14743973

Sources:
NCI
TEMSIROLIMUS ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28676933

Sources:
PharmGKB
METHYLPREDNISOLONE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14583680

Sources:
PharmGKB
RISPERIDONE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29723928 29443543 26129906 24589909 23609392 19997080

Sources:
PharmGKB
SAQUINAVIR ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PHENOTHIAZINE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16750172

Sources:
NCI
E-FLUPENTIXOL ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PROPAFENONE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
TENIPOSIDE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
QUININE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PREDNISOLONE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25582575 14583680

Sources:
PharmGKB
CYTARABINE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25567217 25558979 20938465 16331627

Sources:
PharmGKB
PRAVASTATIN ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15616150 19667110

Sources:
NCI PharmGKB
CRIZOTINIB ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26870817

Sources:
CIViC
DILTIAZEM ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SIMVASTATIN ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15616150 19891551 19802823 16321621

Sources:
NCI PharmGKB
TEMOZOLOMIDE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31624332

Sources:
PharmGKB
SIMEPREVIR ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DAUNORUBICIN ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10500777 25567217 25558979 20938465 16331627

Sources:
NCI PharmGKB
PHENOBARBITAL ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16928449 25846690

Sources:
NCI PharmGKB
BLEOMYCIN ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25637052

Sources:
PharmGKB
VINCRISTINE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344 25637052 25582575 22016816 18408561

Sources:
PharmGKB
OXCARBAZEPINE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28837897

Sources:
PharmGKB
INDINAVIR ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
BEPRIDIL ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUPHENAZINE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LOPERAMIDE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CIMETIDINE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VINBLASTINE ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20363635 21348461

Sources:
DTC
DOXORUBICIN ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11408511 29938344 22016816 25637052 18377430 25582575 18408561

Sources:
NCI PharmGKB
FLUVASTATIN ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16002074

Sources:
PharmGKB
PREDNISONE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25637052 12175731

Sources:
PharmGKB
LOVASTATIN ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15616150 10213372

Sources:
NCI PharmGKB
CHEMBL533293 ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
OMEPRAZOLE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29377228 15976989

Sources:
PharmGKB
MAPROTILINE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SIROLIMUS ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14569063 28676933 23073467

Sources:
NCI PharmGKB
GEFITINIB ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16651435 27089937 25554506 15155841

Sources:
NCI PharmGKB
DIGOXIN ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16674925 15969931

Sources:
NCI
CAPECITABINE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22026922 21142915

Sources:
PharmGKB
MITOMYCIN ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
HYDROCORTISONE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16873536

Sources:
NCI PharmGKB
ASTEMIZOLE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ANASTROZOLE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FELODIPINE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LANSOPRAZOLE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17190370

Sources:
PharmGKB
LAMIVUDINE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23996099

Sources:
PharmGKB
METHADONE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15876424

Sources:
NCI
GABAPENTIN ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17328248

Sources:
NCI
NICARDIPINE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VEMURAFENIB ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23116250

Sources:
PharmGKB
FENOFIBRATE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16316932

Sources:
NCI
PROPOFOL ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29755652

Sources:
PharmGKB
CLOZAPINE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27168101 22722500 19593168

Sources:
PharmGKB
TOPOTECAN ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DESIPRAMINE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EPIRUBICIN ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15161039

Sources:
NCI
TETRACYCLINE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
COLCHICINE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25876828

Sources:
TEND PharmGKB
IBUPROFEN ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11583291

Sources:
NCI
PACLITAXEL ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16467099 16289636 15876424

Sources:
DTC NCI CIViC
OLANZAPINE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29443543 18086475 17038883

Sources:
PharmGKB
CARVEDILOL ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CAMPTOTHECIN ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9918583

Sources:
NCI
MIFEPRISTONE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
MELPHALAN ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ERYTHROMYCIN ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
KETOCONAZOLE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RIFAMPIN ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
IMATINIB ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15155841 15805252

Sources:
NCI
AMIODARONE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
METHYLPHENIDATE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23771192

Sources:
PharmGKB
LITHIUM ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21449676

Sources:
PharmGKB
CURCUMIN ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15090070

Sources:
NCI PharmGKB
NICOTINE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16191663

Sources:
NCI
NIFEDIPINE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10213372

Sources:
NCI
CISPLATIN ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344 23746184 22016816 21332314 20530282

Sources:
PharmGKB
LAMOTRIGINE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ETOPOSIDE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12969965

Sources:
PharmGKB
IRINOTECAN ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27845419

Sources:
PharmGKB
7-ETHYL-10-HYDROXYCAMPTOTHECIN ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DEXAMETHASONE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29177954 18408561

Sources:
PharmGKB
SEVOFLURANE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RUCAPARIB ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ATENOLOL ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
MIDAZOLAM ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EVEROLIMUS ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DISULFIRAM ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DOCETAXEL ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21151855

Sources:
PharmGKB
CARBOPLATIN ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11157479

Sources:
NCI
MITOXANTRONE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ERLOTINIB ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DIPYRIDAMOLE ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL ABCB1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16892554

Sources:
NCI
TAMOXIFEN ABCB1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
HALOPERIDOL ABCB1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PROGESTERONE ABCB1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SORAFENIB ABCB1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

Ensembl: ENSG00000085563
- Version: 101_38
Alternate Names:

ABCB1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TEND: P08183
- Version: 01-August-2011
Alternate Names:

ENSG00000085563 Ensembl Gene Id

P08183 Uniprot Accession

5243 Entrez Gene Id

Gene Info:

Transmembrane Helix Count 12

Target Subclass ABCB

Target Subclass Active_transporters

Publications:
TdgClinicalTrial: P08183
- Version: January-2014
Alternate Names:

ABCB1 Gene Symbol

Gene Info:

Target Class Transporters

Target Subclass TC:3.A.1.201.1

Publications:
HopkinsGroom: P08183
- Version: 11-September-2012
Alternate Names:

MDR1_HUMAN Uniprot Id

ENSG00000085563 Ensembl Gene Id

MULTIDRUG RESISTANCE PROTEIN 1 Uniprot Protein Name

Gene Info:

Uniprot Status Swiss-Prot

Interpro Acc IPR001140

Interpro Short Name ABC_transptr_TM_dom

Gene Categories:

ABC TRANSPORTER, DRUGGABLE GENOME

Publications:
RussLampel: ENSG00000085563
- Version: 26-July-2011
Alternate Names:

MULTIDRUG RESISTANCE PROTEIN 1 (P-GLYCOPROTEIN 1) (CD243 ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P08183] Description

ENSG00000085563 Ensembl Gene Id

ABCB1 Display Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:

PharmGKB: ABCB1

Version: 18-August-2020

Alternate Names:

PA267 PharmGKB ID

Gene Info:

Publications:

Baietto L et al., 2015, Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients., J Antimicrob Chemother

Ehmann F et al., 2014, European Medicines Agency initiatives and perspectives on pharmacogenomics., Br J Clin Pharmacol

Saiz-Rodríguez M et al., 2018, Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants., Basic Clin Pharmacol Toxicol

CIViC: ABCB1

Version: 14-September-2020

Alternate Names:

5243 Entrez Gene ID

4244 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Gréen et al., 2006, mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy., Clin. Cancer Res.

Deguchi Y et al., 2008, Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines., Leuk Res

Katayama R et al., 2015, P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer., EBioMedicine

NCI: ABCB1

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Kim et al., 1999, Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein., Pharm. Res.

Banerjee et al., 1992, Down-regulation of ras and myc expression associated with mdr-1 overexpression in adriamycin-resistant tumor cells., Cell. Mol. Biol.

Ando et al., 2000, Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells., Leukemia

DTC: ABCB1

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Cunningham CW et al., 2008, Opioids and efflux transporters. Part 2: P-glycoprotein substrate activity of 3- and 6-substituted morphine analogs., J Med Chem

Colabufo NA et al., 2008, Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents., J Med Chem

Juvale K et al., 2012, Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein., Bioorg Med Chem

HingoraniCasas: ENSG00000085563
- Version: 31-May-2017
Alternate Names:

ENSG00000085563 Gene Symbol

ABCB1 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
ChemblInteractions: MDR1
- Version: chembl_23
Alternate Names:

PGY1 GENE_SYMBOL

ABCB1 GENE_SYMBOL

Multidrug resistance protein 1 UNIPROT

Gene Info:

Publications:
HumanProteinAtlas: ABCB1
- Version: 19.3
Alternate Names:

ENSG00000085563 Ensembl Gene ID

ABC20 Human Protein Atlas Gene Synonym

CD243 Human Protein Atlas Gene Synonym

Gene Info:

Gene Categories:

TRANSPORTER, CELL SURFACE, ENZYME

Publications:
GO: ABCB1
- Version: 01-February-2022
Alternate Names:

MDR1 GO Gene Synonym

PGY1 GO Gene Synonym

Gene Info:

Gene Categories:

CELL SURFACE, ABC TRANSPORTER

Publications:
Tempus: ABCB1
- Version: 11-November-2018
Alternate Names:

ABCB1 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
TTD: Multidrug resistance protein 1
- Version: 2020.06.01
Alternate Names:

ABCB1 TTD Gene Abbreviation

T25258 TTD Target ID

Gene Info:

Publications:
Pharos: ABCB1
- Version: 01-February-2022
Alternate Names:

Multidrug resistance protein 1 Gene Name

P08183 UniProt ID

Gene Info:

Gene Categories:

TRANSPORTER

Publications:

Mechanism of Interaction	P-glycoprotein 1 inhibitor
Direct Interaction	yes
Trial Name	tariquidar

ENSG00000085563	Ensembl Gene Id
P08183	Uniprot Accession
5243	Entrez Gene Id

MDR1_HUMAN	Uniprot Id
ENSG00000085563	Ensembl Gene Id
MULTIDRUG RESISTANCE PROTEIN 1	Uniprot Protein Name

MULTIDRUG RESISTANCE PROTEIN 1 (P-GLYCOPROTEIN 1) (CD243 ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:P08183]	Description
ENSG00000085563	Ensembl Gene Id
ABCB1	Display Id

PGY1	GENE_SYMBOL
ABCB1	GENE_SYMBOL
Multidrug resistance protein 1	UNIPROT

Trial Name	zosuquidar, LY335979
Novel drug target	Novel Target

ABCB1 Gene Record

ABCB1 5243 Druggable GenomeDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 16273216 14612920 24720452

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name zosuquidar, LY335979 Novel drug target Novel Target

PMIDs: 18157518

Sources: TdgClinicalTrial PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction P-glycoprotein 1 inhibitor Direct Interaction yes Trial Name tariquidar

PMIDs: 21657271

Sources: DTC TdgClinicalTrial ChemblInteractions PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11754602

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24992153

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17664327

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16271474

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16271474

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11754602

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18311899

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11754602

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21348461

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18311899

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11754602

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16289636

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22112540

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9816258

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22112540

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
16273216 14612920 24720452

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name zosuquidar, LY335979

Novel drug target Novel Target

PMIDs:
18157518

Sources:
TdgClinicalTrial PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction P-glycoprotein 1 inhibitor

Direct Interaction yes

Trial Name tariquidar

PMIDs:
21657271

Sources:
DTC TdgClinicalTrial ChemblInteractions PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11754602

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
24992153

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
17664327

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
16271474

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
16271474

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
11754602

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
18311899

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
11754602

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
21348461

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
18311899

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
11754602

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
16289636

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22112540

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
9816258

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
22112540

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
18257545

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23273047

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22148475

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
18257545

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
8786364

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
18311899

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
25239468

Sources:
PharmGKB